Extended-release niacin (nicotinic acid)/laropiprant

Drugs

Volumn 69, Issue 12, 2009, Pages 1665-1679

  Perry, Caroline M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT PLUS NIACIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIDAZOLAM; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; ERYTHEMA; EVENING DOSAGE; FLUSHING; GLUCOSE BLOOD LEVEL; HEPATITIS; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INCIDENCE; MYOPATHY; NAUSEA; NONHUMAN; PARESTHESIA; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ANTILIPEMIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL, LDL; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DRUG INTERACTIONS; FLUSHING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; NIACIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PROSTAGLANDIN;

EID: 68949083513     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11203730-000000000-00000     Document Type: Review

References (28)

1. Bays H. Safety of niacin and simvastatin combination therapy. Am J Cardiol 2008; 101 (8 Suppl. 1): 3-8B
2. Kamanna V, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008; 101 (8 Suppl. 1): 20-6B
3. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55
4. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001 May 16; 285 (19): 2486-97
5. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Eduction Program Adult Treament Panel III guidelines. Circulation 2004 Jul 13; 110 (2): 227-39
6. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008 Dec; 62 (12): 1959-70
7. Guyton JR, Simmons PD. Flushing and other dermatologic adverse events associated with extended-release niacin therapy. J Clin Lipidol 2009; 3 (2): 101-8
8. Davidson MH. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol 2008; 101 Suppl.: 14-9B
9. Paolini JF,Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008 Mar 1; 101 (5): 625-30
10. Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009; 104: 74-81
11. Lai E, De Lepeleire I, Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 2007 Jun; 81 (6): 849-57
12. Bays HE, Maccubbin D, Meehan AG, et al. Blood pressurelowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin Ther 2009 Jan; 31 (1): 115-22
13. Dishy V, Liu F, Ebel DL, et al. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol 2009 Apr; 49 (4): 416-22
14. Cheng K, Wu T, Wu K, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 2006; 103: 6682-7
15. Lai E, Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmacodynamics and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2008 Jun; 83 (6): 840-7
16. Merck Sharp & Dohme Ltd. Tredaptive European prescribing information [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ tredaptive/H-889-PI-en.pdf [Accessed 2009 Aug 3]
17. Sanford M, Curran MP. Niacin extended-release/simvastatin. Drugs 2008; 68 (16): 2372-87
18. McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 2005; 65 (18): 2719-40
19. Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 2007 Dec 3; 100 (11A): S53-61
20. Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006; 97: 477-9
21. Bays HE, Rader DJ. Does nicotinic acid (niacin) lower blood pressure? Int J Clin Pract 2009 Jan; 63 (1): 151-9
22. Stroh M, Wenning L, Luo WL, et al. Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency. Am J Ther. Epub 2009 May 19
23. Schwartz JI, Liu F, Stroh M, et al. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin. Am J Ther 2009, 215-23
24. Gleim G, Liu N, Thompson-Bell S, et al. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol 2009; 16 (2): 90-7
25. Kush D, Kim H-S, Hu DY, et al. Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia. J Clin Lipidol 2009 May; 3 (3): 179-86
26. Kush D, Hu DY, Ye P, et al. Flushing profile of extendedrelease niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Cardiology 2009 Jul 15; 114 (3): 192-8
27. Bays HE, MacCubbin D, Shah A, et al. Lipid-altering efficacy of ER niacin/laropiprant in dyslipidemic patients with metabolic syndrome [abstract no. 86-OR]. Diabetes 2008 Jun; 57 (Suppl. 1): A27
28. McKenney J, Bays H, Koren MJ, et al. Safety profile of extended-release niacin/laropiprant in patients with dyslipidemia [abstract no. 1028-168 plus poster]. J Am Coll Cardiol 2008 Mar 11; 51 (10 Suppl. A): 334